Valuation: Alterity Therapeutics Limited

Market Cap 80.43M 70.59M 65.73M 60.46M 113M 7.68B 115M 780M 305M 3.81B 302M 295M 13.17B P/E 2026 *
-0.31x
P/E 2027 * -0.31x
Enterprise Value 35.25M 30.93M 28.8M 26.49M 49.66M 3.37B 50.52M 342M 134M 1.67B 132M 129M 5.77B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 33x
Free-Float
91.78%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alterity Therapeutics Limited

1 day-2.14%
1 week-8.33%
Current month-14.99%
1 month-5.29%
3 months-0.33%
6 months+35.06%
Current year+48.21%
1 week 4.46
Extreme 4.46
4.75
1 month 4.46
Extreme 4.46
5.89
Current year 3.02
Extreme 3.0208
5.89
1 year 2.66
Extreme 2.66
5.89
3 years 1
Extreme 1.001
7
5 years 1
Extreme 1.001
18.2
10 years 1
Extreme 1.001
66.9
Manager TitleAgeSince
Chief Executive Officer 65 07/01/2021
Director of Finance/CFO - 30/09/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 29/07/2005
Director/Board Member 47 08/08/2011
Director/Board Member 65 21/11/2025
Change 5-day change 1-year change 3-year change Capi.($)
-2.14%-8.33% - - 80.43M
+1.29%+5.15%-2.79%+11.64% 47.88B
-2.24%+0.31%+393.45%+615.13% 39.09B
+1.40%+3.69%+12.21%+46.79% 36.75B
+13.94%+20.49%+22.85%+7.42% 40.55B
-0.73%+3.38%+4.94%+41.45% 27.96B
+0.40%-0.30% - - 16.77B
-3.12%+7.39%+26.03%+124.08% 15.94B
-1.08%-4.00%+1.89%+8.28% 13.55B
+6.79%+8.17%-4.97%-28.52% 13.81B
Average +1.43%+4.64%+56.70%+103.28% 28.03B
Weighted average by Cap. +2.36%+5.03%+72.74%+125.16%

Financials

2026 *2027 *
Net sales 2.57M 2.25M 2.1M 1.93M 3.62M 245M 3.68M 24.9M 9.75M 122M 9.64M 9.43M 420M 1.2M 1.05M 981K 902K 1.69M 115M 1.72M 11.64M 4.55M 56.87M 4.51M 4.41M 196M
Net income -14.64M -12.85M -11.97M -11.01M -20.63M -1.4B -20.99M -142M -55.57M -694M -54.97M -53.79M -2.4B -29.66M -26.03M -24.24M -22.29M -41.79M -2.83B -42.51M -288M -113M -1.41B -111M -109M -4.86B
Net Debt -45.19M -39.66M -36.93M -33.97M -63.67M -4.32B -64.76M -438M -171M -2.14B -170M -166M -7.4B -40.88M -35.88M -33.41M -30.73M -57.6M -3.91B -58.59M -396M -155M -1.94B -153M -150M -6.69B
Logo Alterity Therapeutics Limited
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Employees
9
Date Price Change Volume
28/07/26 USD 4.565 -2.14% 2,211
27/07/26 USD 4.665 +2.75% 3,895
24/07/26 USD 4.540 -3.20% 17,932
23/07/26 USD 4.690 -0.21% 9,553
22/07/26 USD 4.700 -5.62% 11,650
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.5300AUD
Average target price
2.280AUD
Spread / Average Target
+330.19%

Quarterly revenue - Rate of surprise